Theratechnologies Regains Rights to EGRIFTA(R) (tesamorelin for injection) in the United States
Marketwire - Thu May 01, 6:04AM CDT
Theratechnologies Inc. (TSX: TH) today announced the closing of the transaction with EMD Serono, Inc. in which Theratechnologies regained all rights to EGRIFTA(R) (tesamorelin for injection) in the United States, including its commercialisation rights.
Health Canada Approves EGRIFTA(TM) (tesamorelin for injection) and Theratechnologies Regains Canadian Commercialization Rights to EGRIFTA(TM)
Marketwire - Wed Apr 30, 11:35AM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that it has received a notice of compliance (regulatory approval) from Health Canada for EGRIFTA(TM) (tesamorelin for injection).
Theratechnologies Announces Financial Results for First Quarter of 2014
Marketwire - Mon Apr 14, 3:31PM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the first quarter ended February 28, 2014.
Theratechnologies to Announce Financial Results for the First Quarter of 2014
Marketwire - Tue Apr 08, 3:11PM CDT
Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the first quarter ended February 28, 2014, on Monday, April 14, 2014, after markets close.
Theratechnologies Announces Financial Results for Fiscal Year 2013
Marketwire - Thu Feb 27, 6:02AM CST
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the year ended November 30, 2013.
Theratechnologies to Announce Financial Results for Fiscal Year 2013
Marketwire - Tue Feb 25, 4:01PM CST
Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the fiscal year ended November 30, 2013, on Thursday, February 27, 2014, before markets open.
Theratechnologies Inc.: Short Supply of EGRIFTA(R) Announced
Marketwire - Fri Feb 14, 5:01AM CST
Theratechnologies Inc. (TSX: TH) announced today that it expects current inventory of EGRIFTA(R) (tesamorelin for injection) to be depleted in the coming weeks due to a combination of manufacturing delays and issues observed during the production of new batches of EGRIFTA(R). The depletion of the inventory will result in a shortage of EGRIFTA(R) and an eventual stock-out. EMD Serono, Inc. has notified the United States Food and Drug Administration about this product shortage.
IIROC Trade Resumption - Theratechnologies Inc.
Newsfile Corp - Fri Dec 13, 7:46AM CST
Trading resumes in:
IIROC Trade Halt - Theratechnologies Inc.
Newsfile Corp - Fri Dec 13, 7:44AM CST
The following issues have been halted by IIROC:
Theratechnologies Regains U.S. Marketing Rights to EGRIFTA(R)
Marketwire - Fri Dec 13, 7:30AM CST
Theratechnologies Inc. (TSX: TH) today announced that it has reached an agreement with EMD Serono to regain all rights under the current collaboration and licensing agreement entered into in 2008 with EMD Serono, including commercialization rights for EGRIFTA(R) (tesamorelin for injection) in the United States.
Theratechnologies Resumes Shipment of Tesamorelin to EMD Serono
Marketwire - Tue Dec 03, 3:54PM CST
Theratechnologies Inc. (TSX: TH) is pleased to announce that it has resumed shipment of EGRIFTA(TM) (tesamorelin for injection) to EMD Serono in the United States today.